Lung cancer begins in the lungs, and it may spread to lymph nodes or other organs in the body. There are mainly two types of lung cancer:-&nbsp;
<ul>
<li>Small Cell Lung Cancer (SCLC)&nbsp;</li>
<li>Non-Small Cell Lung Cancer (NSCLC)&nbsp;</li>
</ul>
&nbsp;
NSCLC can be defined as epithelial lung cancer other than SCLC. NSCLC emerges from the epithelial cells of the lung of the central bronchi to terminal alveoli. It is mainly subcategorized into&nbsp;
<ul>
<li>Adenocarcinomas</li>
<li>Squamous Cell Carcinomas</li>
<li>Large Cell Carcinomas&nbsp;</li>
<li>Adenosquamous Carcinomas&nbsp;</li>
<li>Sarcomatoid Carcinomas</li>
</ul>
&nbsp;
&nbsp;
Non-Small Cell Lung Cancer Epidemiological Segmentation&nbsp;
The Epidemiological Segmentation of Non-Small Cell Lung Cancer in 7MM from 2017 to 2030 is segmented as:-&nbsp;
<ul>
<li>Total Incident cases of NSCLC patients</li>
<li>Total Incident cases of NSCLC patients by Histology</li>
<li>Total Diagnosed cases of NSCLC patients by Stages</li>
<li>Total NSCLC cases of patients by Genetic mutation/Biomarkers</li>
<li>Total Treated cases of NSCLC patients by Line of Therapies</li>
</ul>
&nbsp;
Non-Small Cell Lung Cancer Epidemiology&nbsp;
<ul>
<li>NSCLC is the most common type of lung cancer accounted for around 85% of all lung cancers.</li>
<li>The total NSCLC incident cases in the 7MM in 2017 were 484,726 cases.</li>
</ul>
&nbsp;
<a style="color: #0066cc; background-color: transparent;" href="https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-market" target="_blank" rel="noopener noreferrer">Non-Small Cell Lung Cancer Market</a>
Non-Small Cell Lung Cancer Market is anticipated to increase with a CAGR of 10.7% for the Study Period of 2017-2030.
&nbsp;
Non-Small Cell Lung Cancer Market Drivers
<ul>
<li>Increasing the use of biomarker testing</li>
<li>Increasing Incidence of NSCLC</li>
<li>Increase in the mutation-specific trials activity and approval</li>
<li>Competitive landscape</li>
</ul>
&nbsp;
Non-Small Cell Lung Cancer Market Barriers
<ul>
<li>Cost-effectiveness of therapies</li>
<li>Small patient populations for specific subsets of NSCLC</li>
<li>Cost of therapies</li>
<li>Generic or biosimilar erosion</li>
</ul>
&nbsp;
Non-Small Cell Lung Cancer Emerging Drugs
The Emerging drugs of the Non-Small Cell Lung Cancer market are&nbsp;
<ul>
<li>Nazartinib (EGF816)</li>
<li>Tepmetko (tepotinib)</li>
<li>Merestinib</li>
<li>Vemurafenib Plus Cobimetinib</li>
<li>X-396 (Ensartinib)</li>
<li>Plinabulin</li>
<li>Tedopi (OSE2101)</li>
<li>SAR408701</li>
<li>TAK-788</li>
<li>Veliparib (ABT-888)</li>
</ul>
And many others.&nbsp;
&nbsp;
Non-Small Cell Lung Cancer Key Players
The key players in the Non-Small Cell Lung Cancer market are
<ul>
<li>Novartis Pharmaceuticals</li>
<li>Merck KGaA</li>
<li>Eli Lilly and Company</li>
<li>Hoffmann-La Roche</li>
<li>Xcovery</li>
<li>BeyondSpring Pharmaceuticals</li>
<li>OSE Immunotherapeutics</li>
<li>Sanofi</li>
<li>Takeda</li>
<li>AbbVie</li>
</ul>
And many others.&nbsp;

Non-Small Cell Lung Cancer Market

Non-Small Cell Lung Cancer Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.